News
- Author:
- Liam Davenport
Publish date: October 28, 2025
Results from a crossover trial suggest retreatment with an anti-EGFR can be effective in patients with mCRC.
News
- Author:
- Liam Davenport
Publish date: October 28, 2025
Questions about these antibody-drug conjugates remain, but provide hope for patients who are not candidates for immunotherapy.
News
- Author:
- Liam Davenport
Publish date: March 7, 2025
Treating ulcerative colitis beyond the first line of therapy is “becoming challenging” because there are several therapeutic classes and drugs to c...
News
- Author:
- Liam Davenport
Publish date: March 6, 2025
Moderate anxiety in Crohn’s disease increased clinical flare risk, as did severe anxiety in both Crohn’s disease, and ulcerative colitis and IBD un...
News
- Author:
- Liam Davenport
Publish date: March 6, 2025
There were distinct differences in the microbial composition between healthy control individuals and patients with Crohn’s disease and with ulcerat...
News
- Author:
- Liam Davenport
Publish date: March 4, 2025
The overall neoplasia detection rate was 11.4%, “which is very similar to what has previously been seen in the literature,” said Dr Chandni Radia.<...
News
- Author:
- Liam Davenport
Publish date: March 4, 2025
The discovery represents the “tip of the iceberg” in terms of understanding how antibody response could predict IBD onset.
News
- Author:
- Liam Davenport
Publish date: December 18, 2024
Patients with myeloma or cervical cancer who are treated with some antibody-drug conjugates also may experience serious ocular toxicity adverse eve...
News
- Author:
- Liam Davenport
Publish date: December 13, 2024
Could AMPs, which can target and rupture cell membranes, offer new options for antibiotic resistance?
News
- Author:
- Liam Davenport
Publish date: November 14, 2024
“Removal of gender from clinical risk scoring could simplify the approach to which patients with AF should be offered oral anticoagulation.”
News
- Author:
- Liam Davenport
Publish date: November 12, 2024
Barzolvolimab is an anti-KIT monoclonal antibody that inhibits the activation of and depletes mast cells.
News
- Author:
- Liam Davenport
Publish date: November 12, 2024
Children at the lower percentiles of height receiving prompt treatment with dupilumab “were able to rapidly move through the centiles over the 16 w...
News
- Author:
- Liam Davenport
Publish date: November 12, 2024
Nemolizumab was associated with “ongoing clinically meaningful improvements in itch, skin lesions, and sleep disturbance,” reported Dr. Diamant Tha...
News
- Author:
- Liam Davenport
Publish date: November 12, 2024
Ruxolitinib cream twice daily resulted in “significant improvements in cutaneous lichen planus disease severity vs vehicle” after 16 weeks of treat...
News
- Author:
- Liam Davenport
Publish date: November 5, 2024
“Efficacy and health-related quality-of-life outcomes were maintained through 2 years of treatment,” according to the study presenter.
